389 related articles for article (PubMed ID: 24638152)
1. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
[TBL] [Abstract][Full Text] [Related]
2. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
Klingenstein A; Haug AR; Zech CJ; Schaller UC
Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
[TBL] [Abstract][Full Text] [Related]
3. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
4. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
Kim AY; Frantz S; Brower J; Akhter N
J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
[TBL] [Abstract][Full Text] [Related]
5. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.
Piana PM; Gonsalves CF; Sato T; Anne PR; McCann JW; Bar Ad V; Eschelman DJ; Parker L; Doyle LA; Brown DB
J Vasc Interv Radiol; 2011 Oct; 22(10):1373-9. PubMed ID: 21764600
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
Gunduz S; Ozgur O; Bozcuk H; Coşkun HS; Ozdogan M; Erkilic M; Sindel T; Yldlzs A; Ylmaz S; Boz A; Aydin F; Karayalçin B; Savas B
Hepatogastroenterology; 2014 Sep; 61(134):1529-34. PubMed ID: 25436337
[TBL] [Abstract][Full Text] [Related]
7. A first report of radioembolization for hepatic metastases from ocular melanoma.
Kennedy AS; Nutting C; Jakobs T; Cianni R; Notarianni E; Ofer A; Beny A; Dezarn WA
Cancer Invest; 2009 Jul; 27(6):682-90. PubMed ID: 19219675
[TBL] [Abstract][Full Text] [Related]
8. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver.
Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Minor DR; Sze DY
J Vasc Interv Radiol; 2012 Mar; 23(3):323-30.e1. PubMed ID: 22277275
[TBL] [Abstract][Full Text] [Related]
10. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
[TBL] [Abstract][Full Text] [Related]
11. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
13. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
[TBL] [Abstract][Full Text] [Related]
14. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
[TBL] [Abstract][Full Text] [Related]
15. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience.
Gonsalves CF; Eschelman DJ; Sullivan KL; Anne PR; Doyle L; Sato T
AJR Am J Roentgenol; 2011 Feb; 196(2):468-73. PubMed ID: 21257902
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 Radioembolization of Advanced, Unresectable Breast Cancer Liver Metastases-A Single-Center Experience.
Pieper CC; Meyer C; Wilhelm KE; Block W; Nadal J; Ahmadzadehfar H; Willinek WA; Schild HH
J Vasc Interv Radiol; 2016 Sep; 27(9):1305-1315. PubMed ID: 27461588
[TBL] [Abstract][Full Text] [Related]
17. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
[TBL] [Abstract][Full Text] [Related]
18. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
Memon K; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Gates VL; Atassi B; Newman S; Omary RA; Benson AB; Salem R
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):887-94. PubMed ID: 22137020
[TBL] [Abstract][Full Text] [Related]
19. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
[TBL] [Abstract][Full Text] [Related]
20. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V
Oncology; 2014; 86(1):24-32. PubMed ID: 24401529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
